Marshall Wace North America L.P. lessened its stake in shares of Loxo Oncology Inc (NASDAQ:LOXO) by 49.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 154,837 shares of the biopharmaceutical company’s stock after selling 152,972 shares during the period. Marshall Wace North America L.P. owned approximately 0.51% of Loxo Oncology worth $26,451,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. First Mercantile Trust Co. grew its position in Loxo Oncology by 45.8% during the 3rd quarter. First Mercantile Trust Co. now owns 1,029 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 323 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in Loxo Oncology during the 2nd quarter worth approximately $209,000. LPL Financial LLC purchased a new stake in Loxo Oncology during the 3rd quarter worth approximately $244,000. Pacer Advisors Inc. purchased a new stake in Loxo Oncology during the 3rd quarter worth approximately $255,000. Finally, Aperio Group LLC purchased a new stake in Loxo Oncology during the 2nd quarter worth approximately $306,000. 96.81% of the stock is currently owned by institutional investors.

NASDAQ LOXO traded down $0.39 on Friday, hitting $134.78. 1,907 shares of the company’s stock traded hands, compared to its average volume of 350,088. Loxo Oncology Inc has a 1-year low of $75.78 and a 1-year high of $208.95. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of -25.42 and a beta of 2.21.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.24). Loxo Oncology had a negative net margin of 43.49% and a negative return on equity of 16.42%. The business had revenue of $42.47 million for the quarter, compared to analyst estimates of $38.55 million. During the same quarter in the previous year, the firm posted ($2.45) earnings per share. Sell-side analysts forecast that Loxo Oncology Inc will post -2.34 earnings per share for the current fiscal year.

Several research firms have weighed in on LOXO. BidaskClub raised shares of Loxo Oncology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 29th. Zacks Investment Research cut shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, October 17th. Piper Jaffray Companies set a $200.00 price objective on shares of Loxo Oncology and gave the company a “buy” rating in a research note on Wednesday, September 26th. JMP Securities decreased their price objective on shares of Loxo Oncology from $221.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, November 13th. Finally, Goldman Sachs Group started coverage on shares of Loxo Oncology in a research note on Monday, September 17th. They set a “neutral” rating and a $165.00 price objective for the company. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Loxo Oncology currently has an average rating of “Buy” and a consensus target price of $189.38.

In related news, Director Lori Anne Kunkel sold 5,000 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $170.37, for a total value of $851,850.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $851,850. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Jennifer Burstein sold 2,500 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $166.96, for a total transaction of $417,400.00. Following the completion of the transaction, the vice president now owns 1,250 shares of the company’s stock, valued at $208,700. The disclosure for this sale can be found here. Over the last quarter, insiders sold 102,500 shares of company stock valued at $16,412,950. Company insiders own 17.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://theolympiareport.com/2018/12/07/loxo-oncology-inc-loxo-shares-sold-by-marshall-wace-north-america-l-p.html.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Recommended Story: Outstanding Shares

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.